Federal Panel Schedules Hearing on Possible Creation of AndroGel Lawsuit Litigation in the Northern District of Illinois, Bernstein Liebhard LLP Reports

The Firm is actively investigating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, pulmonary embolism, deep vein thrombosis or another cardiovascular injury after taking AndroGel or another “Low T” medication.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Free Case Review
We are looking forward to the federal Panel’s upcoming hearing on whether to coordinate AndroGel lawsuits in the Southern District of Illinois.

New York, NY (PRWEB) April 16, 2014

A federal Panel has set a date next month to hear oral arguments on whether to transfer all pending and future AndroGel lawsuit (http://www.testosteronelawsuit2014.com/) filings to the U.S. District Court, Northern District of Illinois, Bernstein Liebhard LLP reports.

According to a recent Order, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear oral arguments on May 29th, 2014 in Chicago that relate to the potential consolidation of testosterone lawsuits over AndroGel, a “Low T” hormone-raising therapy. The Panel’s Order on April 14th was issued in response to a motion from plaintiffs last month that requested the coordination of AndroGel claims in Illinois federal court. Among other things, the March 28th brief contended that the creation of a multidistrict litigation was necessary to handle the thousands of similar claims over the medication that may be filed in the future. AndroGel lawsuits in this jurisdiction allege strokes, heart attacks, dangerous blood clots and other serious cardiovascular problems, court documents indicate. (In Re: AndroGel Product Liability Litigation, No. 36, JPML)

“We are looking forward to the federal Panel’s upcoming hearing on whether to coordinate AndroGel lawsuits in the Southern District of Illinois, as our lawyers continue to hear from men who were allegedly injured by the “Low T” treatment,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential AndroGel lawsuit evaluations to men who allegedly suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism after taking the medication.

Testosterone Lawsuits over AndroGel

As of March 2014, court documents indicate that some 30 AndroGel lawsuits had been filed in the U.S. District Court, Northern District of Illinois on behalf of men who took the prescription medication. The plaintiffs’ motion from that month states that a number of additional testosterone lawsuits were pending in Pennsylvania and Colorado federal courts.

In speaking to the benefits of a federal AndroGel lawsuit litigation, individuals in these cases say its creation would preserve the resources of the court, parties and witnesses and help avoid duplicative discovery in similar claims over the drug, as well as inconsistent rulings from judges.

All the lawsuits now filed over AndroGel in Illinois federal court allege similar cardiovascular problems caused by the hormone-raising therapy that was originally approved to treat low levels of the hormone, also known as hypogonadism, in conjunction with another medical condition. According to claims however, the medication is frequently prescribed for uses not cleared by the U.S. Food and Drug Administration (FDA), and is instead given to men suffering from low libido, fatigue and other common symptoms of aging. This practice is referred to as “disease mongering,” according to AndroGel lawsuit plaintiffs who accuse its manufacturer of placing sales of its product above patient safety.

All of the claims now filed over AndroGel and other similarly-designed testosterone treatment therapies were filed after the FDA issued a public health alert about the safety of certain “Low T” medications. The federal agency’s warning was released on January 31, 2014 after the findings of two studies linked the use of drugs like AndroGel, Testim and Axiron to heart attacks, strokes and sudden cardiac death in certain men.

Men who allegedly suffered heart attacks, strokes, dangerous blood clots, deep vein thrombosis or pulmonary embolism after taking a “Low T” treatment may be eligible to file a testosterone lawsuit against its manufacturer. To learn more about the fast-developing AndroGel lawsuit litigation, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author